Back

The potential impact of residual inflammation and elevated Lipoprotein (a) levels in long-term cardiovascular patients' survival

1 September 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Risk factors (6) Biomarkers ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Matilde Ferreira

Hospital Funchal, Funchal (Portugal)

5 More presentations in this session

Presentation thumbnail
High-sensitivity CRP to HDL-C ratio as a novel inflammatory-lipid biomarker for mortality risk prediction: a prospective population-based cohort study
Doctor Y. Zhao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Additional value of an integrated Polygenic Risk Score to a conventional tool in the prediction of cardiovascular events in an asymptomatic population
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Relation of Lp(a) with plaque characteristics and clinical events: ATHEROREMO and IBIS_3 cohorts
Doctor J. Veiga-Fernandes Mira (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Circulating Lipoprotein(a) and Non-culprit Lipid-rich Plaques in Acute Coronary Syndrome and Stable Coronary Artery Disease: Findings from Near-infrared Spectroscopy Imaging Analysis
Doctor T. Iwai (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Global cardiac microcalcification activity and the risk of cardiovascular events
Doctor M. Grine (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors (6)

The Event

Event poster

ESC Congress 2025

1 September 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Combined effect of lipoprotein(a) and C-reactive protein on future cardiovascular outcomes after acute myocardial infarction
thumbnail
Congress Presentation
High-sensitive CRP is a reliable biomarker for predicting events in a cardiovascular population
thumbnail
Congress Presentation
Residual inflammation, cholesterol risks and rates of major cardiovascular events in routinely cared patients with atherosclerotic cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources